MGMT and glioblastoma: Another phase III trial, CheckMate 498, which assessed the clinical effect of nivolumab plus radiotherapy versus SOC in patients with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (n = ~275 per arm) also failed to show impact on OS (NCT02617589) [8].